Riptacaine gel and preparation method thereof
Preparation of ripropylene gel by optimizing formula and process solves the problem of low cream stability and release efficiency, achieves high stability and efficient release of the gel, and provides a safe and effective local anesthetic preparation .
Patent Information
- Application Number
- CN202411285120.0
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-09-13
- Publication Date
- 2024-12-06
AI Technical Summary
The existing Riptyrocaine cream has poor physical stability, low release efficiency, and the cream form is inconvenient to use in certain surgical operations.
The lipodoccaine gel was prepared using an optimized formula and process. The pH was adjusted to 9.0 by dissolving drugs and cosolvents at a water bath temperature of 55°C, adding preservatives and pH regulators, and improving the stability of the gel by vacuum treatment. sex and release efficiency.
It significantly improves the physical stability of the gel and the drug release efficiency, is simple to operate, low cost, and is suitable for large-scale production, providing a safer and more effective local anesthesia preparation for clinical practice.
Smart Images

Figure CN119074644A_ABST
Abstract
Description
Technical Field
[0001] The invention belongs to the technical field of biomedicine, and in particular relates to a levocaine gel and a preparation method thereof. The method can improve the stability and release efficiency of the gel and is suitable for clinical cortical local anesthesia. Background Art
[0002] Liprocaine cream, also known as compound lidocaine cream, is a topical local anesthetic preparation and a sodium channel blocker. It is suitable for all types of needle punctures and superficial surgical anesthesia of the skin and mucous membranes. Liprocaine cream was developed by AstraZeneca and was first approved for marketing in Sweden in 1984. The drug is currently available in the following EU member states: Austria, Belgium, Cyprus, Czech Republic, Denmark, Finland, France, Germany, Greece, Ireland, Italy, Latvia, Luxembourg, Malta, Netherlands, Poland, Portugal, Spain, Sweden, United Kingdom, Iceland and Norway. It was listed on the FDA in 1998 (currently withdrawn from the market), originally imported into China in 1998, and launched in Japan in 2012.
[0003] Local anesthesia is a commonly used anesthesia method in medical surgery, which can reduce or eliminate pain during surgery. As a local anesthetic, leprocaine is usually composed of two ingredients, lidocaine and prilocaine, and has the characteristics of rapid onset and long-lasting analgesia. In clinical applications, leprocaine is mostly in the form of cream, which is easy to apply and penetrate locally.
[0004] However, existing leprocaine creams have some limitations. First, the physical stability of the cream is poor and it is easily affected by temperature and humidity, resulting in degradation or separation of the drug components. Second, the release efficiency of the cream is limited by the viscosity of its matrix and the dispersibility of the drug, and rapid and uniform drug release may not be achieved. In addition, the cream form is inconvenient to use in certain surgical procedures, such as when the drug action area needs to be precisely controlled or when it is used in a humid environment.
[0005] To overcome these problems, researchers have been exploring new formulations, such as leprocaine gel. As a semi-solid preparation, gel has good physical stability and adhesion, and can form a protective film on the skin surface, which helps the sustained release and local effect of the drug. However, the leprocaine gel products currently on the market still face problems such as complex preparation process, high cost, and insufficient drug release efficiency. Summary of the invention
[0006] Based on the above deficiencies in the prior art, the present invention provides a new levocaine gel and a preparation method thereof. The method not only improves the physical stability of the gel by optimizing the formula and process, but also significantly improves the in vitro release efficiency of the drug. In addition, the method of the present invention has the advantages of simple operation, low cost, and easy large-scale production, and is expected to provide a safer and more effective local anesthetic preparation for clinical use.
[0007] In order to solve the above technical problems, the present invention provides a method for preparing a levocaine gel, characterized in that it comprises the following steps:
[0008] (1) Add purified water to the matrix, stir and disperse, and let stand for more than 24 hours for later use;
[0009] (2) Stir lidocaine, prilocaine and cosolvent in a water bath at 55°C until completely dissolved;
[0010] (3) Stir and dissolve the preservative and the remaining co-solvent until clear and set aside;
[0011] (4) adding the solution of step (3) to the mixture obtained in step (1), stirring to dissolve;
[0012] (5) The solution of step (2) is added to the mixed solution obtained in step (4), stirred to make the mixture uniform, a pH adjuster is added to adjust the pH to 9.0, stirring is continued for 50 minutes while evacuating the mixture, the material is discharged, and the composite film ointment tube is filled in a clean area and the tail is sealed for packaging.
[0013] As a preferred embodiment of the above technical solution, the preparation method of the levocaine gel provided by the present invention further includes some or all of the following technical features:
[0014] As an improvement of the above technical solution, the matrix is carbomer, hydroxypropyl methylcellulose, sodium carboxymethyl cellulose, and methyl cellulose.
[0015] As an improvement of the above technical solution, the co-solvent includes: propylene glycol, liquid paraffin, poloxamer, and Tween 80.
[0016] As an improvement of the above technical solution, the preservative is at least one of phenoxyethanol, methylparaben, ethylparaben, propylparaben, butylhydroxyanisole, and sorbic acid.
[0017] As an improvement of the above technical solution, the prilocaine gel comprises the following raw materials in parts by weight: 10-50 parts of lidocaine, 10-50 parts of prilocaine, 40-80 parts of a cosolvent, 0.2-7 parts of a preservative, 5-20 parts of a matrix, a pH regulator and 850-950 parts of purified water.
[0018] As an improvement of the above technical solution, the prilocaine gel comprises the following raw materials in parts by weight: 10-50 of lidocaine, 10-50 of prilocaine, 40-80 of propylene glycol, 1-5 of phenoxyethanol, 0.5-2 of methylparaben, 5-20 of carbomer, and appropriate amounts of sodium hydroxide and purified water.
[0019] The present invention also provides a levocaine gel, which is prepared by any of the above methods.
[0020] Compared with the prior art, the technical solution of the present invention has the following beneficial effects:
[0021] The present invention not only improves the physical stability of the gel, but also significantly improves the in vitro release efficiency of the drug. In addition, the method of the present invention has the advantages of simple operation, low cost, and easy large-scale production, and is expected to provide a safer and more effective local anesthetic preparation for clinical use.
[0022] The above description is only an overview of the technical solution of the present invention. In order to more clearly understand the technical means of the present invention, it can be implemented in accordance with the contents of the specification. In order to make the above and other purposes, features and advantages of the present invention more obvious and easy to understand, the following is a detailed description in combination with the preferred embodiments. BRIEF DESCRIPTION OF THE DRAWINGS
[0023] In order to more clearly illustrate the technical solution of the embodiment of the present invention, the drawings of the embodiment are briefly introduced below.
[0024] Figure 1 This is the in vitro release curve of lidocaine in the gel of the product of Example 1 of the present invention;
[0025] Figure 2 This is the in vitro release curve of prilocaine in the gel of the product of Example 1 of the present invention. DETAILED DESCRIPTION
[0026] The specific implementation modes of the present invention are described in detail below, which is a part of this specification. The principles of the present invention are explained through examples. Other aspects, features and advantages of the present invention will become clear through the detailed description.
[0027] Example 1: Preparation of Levitra Gel
[0028] Raw materials preparation:
[0029]
[0030]
[0031] Preparation process:
[0032] (1) Weigh 90% of the prescription amount of purified water into the main mixing tank, add a certain amount of carbomer into the purified water, stir to disperse evenly, and let it stand for more than 24 hours to allow it to fully swell.
[0033] (2) Dissolve lidocaine and prilocaine in propylene glycol in a predetermined ratio at a water bath temperature of 55° C. to form a uniform solution.
[0034] (3) Weigh methylparaben, phenoxyethanol and remaining propylene glycol into a beaker, stir and dissolve until clear, and set aside;
[0035] (4) Add the solutions of step (2) and step (3) into the main mixing tank of step (1), stir to make the mixture uniform, add sodium hydroxide solution to adjust the pH to 9.0, continue stirring for 50 minutes while evacuating the mixture, discharge the mixture, fill it into a composite film ointment tube in a clean area, and seal the tube for packaging.
[0036] Quality Control:
[0037]
[0038] The pH value of the prepared gel is between 8.5 and 9.5 to suit skin use. The viscosity test results satisfy the appropriate adhesion and spreadability.
[0039] The gel prepared in Example 1 was subjected to in vitro testing, specifically as follows:
[0040]
[0041] Attached Figure 1 and 2 The in vitro release curves of lidocaine and prilocaine in the gel are shown respectively. From the figure, we can see that the average cumulative release amounts of lidocaine and prilocaine in the gel prepared in Example 1 of the present invention are better than those of commercially available products.
[0042] Example 2: Optimized preparation of leprocaine gel
[0043] Recipe Adjustment:
[0044] According to the results of Example 1, the concentration of Carbomer 980 was adjusted to optimize the viscosity and stability of the gel. New antioxidants, such as propylparaben, were introduced to improve the microbial stability of the gel matrix. The specific prescription is shown in the table below:
[0045] Types of raw materials Function mg / g Prescription ratio Lidocaine Active ingredients 25 2.5 Prilocaine Active ingredients 25 2.5 Carbomer Matrix 20 2 Methylparaben Antioxidants 1 0.1 Propylparaben Antioxidants 1 0.1 Propylene glycol Dissolve 60 6 Sodium hydroxide pH Adjusters Adjust pH to 9.0 Moderate Purified water Solvents Add water to 1g Moderate
[0046] The sample was prepared using the process steps of Example 1.
[0047] In vitro release experiment:
[0048] The in vitro release experiment was conducted using the vertical diffusion cell method to more accurately simulate the application of the gel on the skin. The specific method is shown in the table below:
[0049]
[0050] The raw materials listed in the present invention, as well as the upper and lower limits and interval values of the raw materials of the present invention, and the upper and lower limits and interval values of the process parameters (such as temperature, time, etc.) can all realize the present invention, and the embodiments are not listed one by one here.
[0051] The above is only a preferred embodiment of the present invention, which certainly cannot be used to limit the scope of rights of the present invention. It should be pointed out that for ordinary technicians in this technical field, several improvements and changes can be made without departing from the principle of the present invention, and these improvements and changes are also regarded as the protection scope of the present invention.
Claims
1. A method for preparing a levocaine gel, characterized in that: The following steps are included: (1) Add purified water to the matrix, stir and disperse, and let stand for more than 24 hours for later use; (2) Stir lidocaine, prilocaine and cosolvent in a water bath at 55°C until completely dissolved; (3) Stir and dissolve the preservative and the remaining co-solvent until clear and set aside; (4) adding the solution of step (3) to the mixture obtained in step (1), stirring to dissolve; (5) The solution of step (2) is added to the mixed solution obtained in step (4), stirred to make the mixture uniform, a pH adjuster is added to adjust the pH to 9.0, stirring is continued for 50 minutes while evacuating the mixture, the material is discharged, and the composite film ointment tube is filled in a clean area and the tail is sealed for packaging.
2. The method for preparing the levocaine gel according to claim 1, wherein: The matrix is carbomer, hypromellose, sodium carboxymethylcellulose and methylcellulose.
3. The method for preparing the levocaine gel according to claim 1, wherein: The cosolvent includes: propylene glycol, liquid paraffin, poloxamer, and Tween 80.
4. The method for preparing the levocaine gel according to claim 1, wherein: The preservative is at least one of phenoxyethanol, methylparaben, ethylparaben, propylparaben, butylhydroxyanisole and sorbic acid.
5. The method for preparing the levocaine gel according to claim 1, wherein: The prilocaine gel comprises the following raw materials in parts by weight: 10-50 parts of lidocaine, 10-50 parts of prilocaine, 40-80 parts of a cosolvent, 0.2-7 parts of a preservative, 5-20 parts of a matrix, a pH regulator and 850-950 parts of purified water.
6. The method for preparing the levocaine gel according to claim 5, characterized in that: The invention discloses a levocaine gel, wherein the weight parts of the constituent materials are: 10-50 parts of lidocaine, 10-50 parts of prilocaine, 40-80 parts of propylene glycol, 1-5 parts of phenoxyethanol, 0.5-2 parts of methylparaben, 5-20 parts of carbomer, and appropriate amounts of sodium hydroxide and purified water.
7. A levocaine gel, characterized in that: The levocaine gel is prepared by the method according to any one of claims 1 to 6.
